{"id":"placebo-capecitabine","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Hand-foot skin reaction"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"15-20","effect":"Nausea"},{"rate":"10-15","effect":"Fatigue"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Stomatitis"},{"rate":"5-10","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that is metabolized preferentially in tumor tissue to its active form, 5-fluorouracil (5-FU). 5-FU inhibits thymidylate synthase, blocking dTMP synthesis and disrupting DNA replication, while also incorporating into RNA to disrupt protein synthesis. This combination of mechanisms leads to apoptosis in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that converts to fluorouracil in tumor tissue, inhibiting thymidylate synthase to disrupt DNA synthesis and induce cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:43.595Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT07456852","phase":"PHASE1, PHASE2","title":"Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-31","conditions":"Malignant Digestive System Neoplasm","enrollment":60},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT03653507","phase":"PHASE3","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-11-28","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":507},{"nctId":"NCT05165069","phase":"PHASE3","title":"The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-01-01","conditions":"Hand-foot Syndrome","enrollment":234},{"nctId":"NCT04550260","phase":"PHASE3","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":640},{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT05008783","phase":"PHASE3","title":"A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-09-17","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":610},{"nctId":"NCT03371017","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-01-11","conditions":"Triple Negative Breast Neoplasms","enrollment":595},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT06622057","phase":"PHASE3","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2025-07-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":195},{"nctId":"NCT04245865","phase":"PHASE2","title":"Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vejle Hospital","startDate":"2020-06-26","conditions":"Colorectal Cancer Metastatic","enrollment":83},{"nctId":"NCT04950322","phase":"PHASE3","title":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-06","conditions":"Gastric or Gastroesophageal Junction Cancer","enrollment":737},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06128252","phase":"NA","title":"Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-09-01","conditions":"Gastric Cancer","enrollment":96},{"nctId":"NCT05869227","phase":"PHASE3","title":"Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"XIANG YANQUN","startDate":"2023-04-28","conditions":"Nasopharyngeal Carcinoma, Maintenance Therapy","enrollment":166},{"nctId":"NCT06722950","phase":"PHASE2","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-12","conditions":"Colorectal Adenoma","enrollment":120},{"nctId":"NCT05063136","phase":"PHASE3","title":"Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-09-28","conditions":"Breast Cancer","enrollment":1979},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT02873195","phase":"PHASE2","title":"Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2017-07-07","conditions":"Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma","enrollment":133},{"nctId":"NCT05163223","phase":"PHASE2","title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","status":"TERMINATED","sponsor":"Aston Sci. Inc.","startDate":"2022-02-28","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT06409429","phase":"PHASE2, PHASE3","title":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":146},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT04908813","phase":"PHASE2","title":"Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-09-29","conditions":"Gastric Cancer","enrollment":150},{"nctId":"NCT06313463","phase":"PHASE3","title":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03","conditions":"Breast Neoplasms","enrollment":375},{"nctId":"NCT06177041","phase":"PHASE3","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","status":"RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2023-12-25","conditions":"Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":486},{"nctId":"NCT06188000","phase":"NA","title":"Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine","status":"UNKNOWN","sponsor":"Universitas Sriwijaya","startDate":"2023-01-01","conditions":"Hand and Foot Skin Reaction, Hand and Foot Syndrome, Capecitabine","enrollment":60},{"nctId":"NCT03802591","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-03-28","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":479},{"nctId":"NCT00745134","phase":"PHASE2","title":"Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-08-11","conditions":"Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma","enrollment":22},{"nctId":"NCT02614794","phase":"PHASE2","title":"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2016-01-28","conditions":"HER2 Positive Breast Cancer","enrollment":612},{"nctId":"NCT00767689","phase":"NA","title":"Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy","status":"TERMINATED","sponsor":"Cook County Health","startDate":"2006-03-21","conditions":"Hand and Foot Syndrome","enrollment":6},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT03770689","phase":"PHASE1, PHASE2","title":"Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-03-20","conditions":"Locally Advanced Rectal Cancer","enrollment":19},{"nctId":"NCT03745170","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-19","conditions":"Gastric Cancer","enrollment":650},{"nctId":"NCT02973737","phase":"PHASE3","title":"A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-07-20","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":279},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT05079438","phase":"PHASE3","title":"Dendrobium Huoshanense Suppository in Rectal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-09-07","conditions":"Locally Advanced Rectal Cancer","enrollment":168},{"nctId":"NCT02314117","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01-20","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":645},{"nctId":"NCT03093870","phase":"PHASE2, PHASE3","title":"Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2017-07-04","conditions":"Biliary Tract Cancer","enrollment":151},{"nctId":"NCT01310231","phase":"PHASE2","title":"A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Ozmosis Research Inc.","startDate":"2011-08-22","conditions":"Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT04833998","phase":"PHASE2","title":"Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine","status":"UNKNOWN","sponsor":"Instituto Brasileiro de Controle do Cancer","startDate":"2019-08-02","conditions":"Hand-foot Syndrome","enrollment":54},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT01774786","phase":"PHASE3","title":"A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-06-10","conditions":"Gastric Cancer","enrollment":780},{"nctId":"NCT03170115","phase":"PHASE2","title":"Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer","status":"TERMINATED","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-11-30","conditions":"Rectal Cancer, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Chemoradiation","enrollment":25},{"nctId":"NCT00437294","phase":"PHASE2","title":"Enzastaurin in Combination of Capecitabine to Treat Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2007-03","conditions":"Breast Cancer","enrollment":86},{"nctId":"NCT04404491","phase":"PHASE3","title":"Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2020-06-01","conditions":"Esophageal Malignant Neoplasm, Local Recurrence","enrollment":240},{"nctId":"NCT04394598","phase":"PHASE2","title":"A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-03-01","conditions":"Locally Advanced Rectal Cancer","enrollment":210},{"nctId":"NCT04164615","phase":"PHASE3","title":"Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection","status":"UNKNOWN","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2016-11-24","conditions":"HER-2-positive Advanced Breast Cancer","enrollment":336},{"nctId":"NCT01751893","phase":"NA","title":"Testing the Effectiveness of Henna on Managing PPE","status":"COMPLETED","sponsor":"Cyprus University of Technology","startDate":"2017-06-01","conditions":"Palmar-plantar Erythrodysesthesia (PPE)","enrollment":56},{"nctId":"NCT01100463","phase":"PHASE1, PHASE2","title":"Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome","status":"COMPLETED","sponsor":"Nanometics (d.b.a. PHD Biosciences)","startDate":"2010-04","conditions":"Palmar-Plantar Erythrodysesthesia, Breast Cancer","enrollment":18},{"nctId":"NCT02251977","phase":"PHASE3","title":"Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2014-09","conditions":"Colorectal Cancer, Chemotherapy-induced Neutropenia","enrollment":196},{"nctId":"NCT02794493","phase":"PHASE3","title":"Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer","status":"COMPLETED","sponsor":"China-Japan Friendship Hospital","startDate":"2015-04-01","conditions":"Hand Foot Syndrome","enrollment":156},{"nctId":"NCT03817411","phase":"PHASE2","title":"Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer","status":"UNKNOWN","sponsor":"Taizhou EOC Pharma Co., Ltd.","startDate":"2019-01-25","conditions":"Gastric Cancer","enrollment":90},{"nctId":"NCT02117479","phase":"PHASE3","title":"Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-03","conditions":"Pancreatic Cancer","enrollment":321},{"nctId":"NCT03821454","phase":"NA","title":"Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-02-01","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT03817658","phase":"PHASE2","title":"A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2019-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":725},{"nctId":"NCT01234337","phase":"PHASE3","title":"Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-02-21","conditions":"Breast Cancer","enrollment":537},{"nctId":"NCT02767752","phase":"PHASE2","title":"Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2016-11","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT00398879","phase":"PHASE2","title":"Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2005-08","conditions":"Colon Cancer","enrollment":381},{"nctId":"NCT02119663","phase":"PHASE3","title":"A Study of Ruxolitinib in Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-06","conditions":"Pancreatic Cancer","enrollment":86},{"nctId":"NCT02120417","phase":"PHASE2","title":"A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-05","conditions":"Breast Cancer","enrollment":149},{"nctId":"NCT01423604","phase":"PHASE2","title":"Study of Ruxolitinib in Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2011-07","conditions":"Pancreatic Cancer","enrollment":136},{"nctId":"NCT03389659","phase":"PHASE3","title":"XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02","conditions":"Vitamin D3","enrollment":750},{"nctId":"NCT02473094","phase":"PHASE2","title":"Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"TERMINATED","sponsor":"University of Campinas, Brazil","startDate":"2015-07","conditions":"Rectal Neoplasms, Adenocarcinoma, Carcinoma","enrollment":3},{"nctId":"NCT00548548","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Adenocarcinoma","enrollment":774},{"nctId":"NCT00296036","phase":"PHASE3","title":"Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-06","conditions":"Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":137},{"nctId":"NCT00887822","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Gastric Cancer","enrollment":202},{"nctId":"NCT01099085","phase":"PHASE3","title":"Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-02","conditions":"Gastric Cancer","enrollment":207},{"nctId":"NCT00399035","phase":"PHASE3","title":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Metastatic Colorectal Cancer","enrollment":1254},{"nctId":"NCT00661102","phase":"PHASE3","title":"A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12","conditions":"Breast Cancer","enrollment":598},{"nctId":"NCT01123473","phase":"PHASE2","title":"Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2010-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer","enrollment":29},{"nctId":"NCT00069095","phase":"PHASE3","title":"A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Colorectal Cancer","enrollment":2035},{"nctId":"NCT02036957","phase":"PHASE1, PHASE2","title":"MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY","status":"UNKNOWN","sponsor":"Basque Health Service","startDate":"2014-02","conditions":"Dermatitis, Adverse Drug Reaction","enrollment":86},{"nctId":"NCT02838238","phase":"PHASE2","title":"X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02137343","phase":"PHASE3","title":"A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-07","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT01697072","phase":"PHASE3","title":"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-10","conditions":"Gastric Cancer","enrollment":609},{"nctId":"NCT00305643","phase":"PHASE3","title":"Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02","conditions":"Breast Cancer, Colorectal Cancer, Pain","enrollment":11},{"nctId":"NCT02590367","phase":"PHASE2, PHASE3","title":"Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Jiangsu Province Hospital of Traditional Chinese Medicine","startDate":"2015-08","conditions":"Peripheral Neuropathy","enrollment":64},{"nctId":"NCT00486213","phase":"PHASE3","title":"Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer","status":"TERMINATED","sponsor":"National Cancer Centre, Singapore","startDate":"2007-06","conditions":"Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":210},{"nctId":"NCT02510118","phase":"PHASE2, PHASE3","title":"Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-06","conditions":"Colon Cancer","enrollment":360},{"nctId":"NCT01609166","phase":"PHASE2","title":"Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-07","conditions":"Hand-foot Syndrome","enrollment":60},{"nctId":"NCT00493636","phase":"PHASE2","title":"1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2007-06","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT00583674","phase":"PHASE2","title":"Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-12","conditions":"Gastrointestinal Cancer","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":154,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + Capecitabine","genericName":"Placebo + Capecitabine","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a small molecule thymidylate synthase inhibitor used in combination with lapatinib and other treatments for various types of cancer, including breast, gastric, and pancreatic cancer. In clinical trials, capecitabine has been studied in combination with lapatinib and either apricoxib or placebo for the treatment of these cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}